Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | CCND1 | P24385 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089778 | 0.84 | ESR1 (0.41) | MAOBALDH1A1TSHR | |
| SCHEMBL5984175 | 0.81 | GABRA1 (0.41) | KDM4EHPGD | |
| SCHEMBL8764034 | 0.79 | TAAR1 (0.42) | MAOBCDK4CCND1TAAR1ADRA2A | |
| SCHEMBL3083361 | 0.77 | CYP1A2 (0.46) | KDM4EHPGDALDH1A1TSHR | |
| SCHEMBL2088676 | 0.77 | SLC22A12 (0.38) | TAAR1ACHEALDH1A1TSHR | |
| SCHEMBL2094571 | 0.76 | TAAR1 (0.46) | TAAR1KDM4EHPGDALDH1A1 | |
| SCHEMBL6394159 | 0.76 | ADRA2A (0.43) | ADRA2AADRA2BADRA2C | |
| SCHEMBL1826769 | 0.76 | PYCR1 (0.41) | TAAR1KDM4EALDH1A1 | |
| SCHEMBL4744351 | 0.76 | HTR2A (0.46) | HPGDTSHR | |
| SCHEMBL65021 | 0.76 | IDO1 (0.58) | TAAR1KDM4EHPGDALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788353-B1 | CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2022-05-18 | — | — | EP | claimed |
| EP-2137139-B1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | CLARIANT SPECIALTY FINE CHEM (FR) | 2014-09-10 | — | — | EP | claimed |
| US-8609882-B2 | Process for deacetalisation of α aminoacetals | CLARIANT SPECIALITY FINE CHEMICALS (FRANCE) (FR) | 2013-12-17 | — | — | US | claimed |
| US-20100137633-A1 | Process For Deacetalisation Of Alpha Aminoacetals | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2010-06-03 | — | — | US | claimed |
| CN-101679223-A | Deacetalization of alpha aminoacetals | CLARIANT SPECIALTY FINE CHEM | 2010-03-24 | — | — | CN | claimed |
| EP-2137139-A1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | Clariant Specialty Fine Chemicals (France) (FR) | 2009-12-30 | — | — | EP | claimed |
| WO-2008125486-A1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2008-10-23 | — | — | WO | claimed |
| US-7432389-B2 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | claimed |
| US-7192983-B2 | Improving storage stability by reacting with hydrogen sulfate lithium- containing compound; aspartyl protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-20 | — | — | US | claimed |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-21 | — | — | US | claimed |
| US-5461152-A | Nucleoside intermediates for antisense oligonucleotides, antiviral agents | CIBA-GEIGY CORPORATION (US) | 1995-10-24 | — | — | US | claimed |
| WO-1995020597-A1 | MODIFIED OLIGONUCLEOTIDES | CIBA-GEIGY AG (CH) | 1995-08-03 | — | — | WO | claimed |
| US-5393878-A | Pyrimidine nucleosides having cyclopentafuran skeleton | CIBA-GEIGY CORPORATION (US) | 1995-02-28 | — | — | US | claimed |
| US-5319080-A | Antiviral agents | CIBA-GEIGY CORPORATION (US) | 1994-06-07 | — | — | US | claimed |
| EP-0577558-A2 | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates | CIBA-GEIGY AG (CH) | 1994-01-05 | — | — | EP | claimed |
| US-5166341-A | Selective antagonist of serotonin 3(5-HT3) receptor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1992-11-24 | — | — | US | claimed |
| EP-0170280-B1 | NOVEL INTERMEDIATES AND PROCESS FOR THE PREPARATION OF 3-ACYLAMINO-1-HYDROXY-2-AZETIDINONES | E.R. Squibb & Sons, Inc. (US) | 1990-12-05 | — | — | EP | claimed |
| US-4826993-A | Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | claimed |
| US-4581170-A | N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones | E. R. SQUIBB & SONS, INC. (US) | 1986-04-08 | — | — | US | claimed |
| EP-0170280-A1 | Novel intermediates and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones | E.R. Squibb & Sons, Inc. (US) | 1986-02-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137633-A1 | Process For Deacetalisation Of Alpha Aminoacetals | ALDH7A1, AADAT, AASDHPPT | MAOB 93/4885CDK4 2471/4885CCND1 1046/4885 |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | MAOB 67/4885CDK4 2257/4885CCND1 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.